ATROPINE SULFATE (atropine sulfate) by Medica Corp is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. First approved in 1990.
Drug data last refreshed 20m ago · AI intelligence enriched 1w ago
Atropine Sulfate is an antimuscarinic agent administered as a metered-dose aerosol inhalation that blocks muscarine-like actions of acetylcholine at muscarinic receptors. It is used to produce mydriasis (pupil dilation) and cycloplegia (loss of accommodation) by preventing muscarinic receptor activation in ocular and respiratory tissues. The drug has been in clinical use since 1990 and remains a standard agent in ophthalmology and emergency medicine.
Product approaching loss of exclusivity with minimal Medicare Part D claims suggests a mature, low-volume market with limited commercial team expansion.
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Atropine Sulfate in Healthy Chinese Volunteers
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Worked on ATROPINE SULFATE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAtropine Sulfate represents a low-opportunity career entry point given zero linked job postings, minimal commercial spending ($17K), and LOE-approaching lifecycle status. Roles on this product are typically small, stable, and focused on legacy account management rather than growth or innovation.